The massive beat and strong cash position support the commercial launch of YARTEMLEA and pipeline development. Monitor upcoming EMA decision on YARTEMLEA in mid-2026 and future milestone payments from Novo Nordisk as key catalysts.
OMER drugs
OMER drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 1 $12.08entry
- T+1 · 8mo ago −9.77%α −9.85% · $10.90
- T+5 · 7mo ago −1.41%α −5.17% · $11.91
- T+20 · 7mo ago +20.53%α +10.81% · $14.56
- T+60 · 5mo ago −17.96%α −31.34% · $9.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omeros reported a massive earnings beat for Q4 2025, driven by a $237.6M gain from the zaltenibart sale to Novo Nordisk and FDA approval of YARTEMLEA. The company turned profitable with GAAP net income of $86.5M ($1.22/share) versus a $31.4M loss in the prior year, while non-GAAP adjusted EPS hit $3.14, crushing consensus. Cash rose to $171.8M and debt was slashed by 47%.
Key Financial Metrics
Key Facts
- Net income for Q4 2025 was $86.5M ($1.22/share), compared to a net loss of $31.4M ($0.54/share) in Q4 2024
- Non-GAAP adjusted net income was $222.5M ($3.14/share), a 670.9% beat vs. consensus of $-0.55
- Recognized $237.6M in net proceeds from the sale of zaltenibart to Novo Nordisk
- FDA approved YARTEMLEA for TA-TMA, with commercial launch underway in January 2026
- Cash and short-term investments totaled $171.8M at year-end; debt reduced by $77.1M (47%) to $87.9M
- OMIDRIA royalties were $9.2M in Q4 2025, down from $10.1M in Q4 2024
Financial Impact
$237.6M one-time gain from asset sale, $133.4M non-GAAP annual adjusted net income, $171.8M cash on hand
Risk Factors
- Future earnings may decline as the $237.6M gain from the zaltenibart sale was non-recurring
- OMIDRIA royalties continue to trend downward, falling to $9.2M in Q4 from $10.1M in the prior year
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-010634 |
| Document: omer20251116_8k.htm | 0001437749-26-010634 |
| Document: 0001437749-26-010634-index-headers.html | 0001437749-26-010634 |
| Document: 0001437749-26-010634-index.html | 0001437749-26-010634 |
| Document: 0001437749-26-010634.txt | 0001437749-26-010634 |
| 8-K Data (Synthetic) | 0001437749-26-010634 |
Track record
12 reports on OMER
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
- Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
- Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
- Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
- Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
- Jul 6, 202619w ago 8-K Neutral 4/10 Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
- Jun 18, 202621w ago 8-K Bullish 5/10 Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers